The aim of this study was to identify factors affecting the pharmacokinetics of mycophenolic acid (MPA) and its 7-O-glucuronide (MPAG) in systemic lupus erythematosus (SLE) patients. Thirty-one SLE patients in remission maintenance phase treated with mycophenolate mofetil (median 1500 mg/d) and prednisolone and followed-up for up to 56 months (median 13 months) were enrolled. Creatinine clearance and metal medication were significant predictors accounting for interindividual variability in the dose-normalized predose plasma concentration (C 0 ) of MPA (adjusted R 2 ‫,503.0؍‬ p‫)10.0؍‬ in a multivariate analysis. Dose-normalized MPAG C 0 was significantly correlated with only creatinine clearance (adjusted R 2 ‫,531.0؍‬ p‫.)30.0؍‬ The free fraction of MPA was significantly correlated with only serum albumin (adjusted R 2 ‫,007.0؍‬ pϽ0.01). The free fraction of MPAG was significantly correlated with serum albumin, metal medication, and age (adjusted R 2 ‫,895.0؍‬ p‫.)20.0؍‬ In conclusion, renal function and co-administered metal influenced the pharmacokinetics of MPA and MPAG in SLE patients in remission maintenance phase.
Mycophenolate mofetil (MMF) is an immunosuppressant widely used in solid organ transplantation. 1) Recently, MMF has also been shown to be effective in autoimmune diseases, including systemic lupus erythematosus (SLE). Mycophenolic acid (MPA), an active moiety of MMF, is mainly metabolized to its 7-O-glucuronide (MPAG).
2) MPAG is pharmacologically inactive but is converted back to MPA during enterohepatic recirculation.
3) MPAG can displace MPA from its albumin binding site and increase its free fraction. 4) MPA is also eliminated into urine as well as MPAG. [5] [6] [7] The pharmacokinetics of MPA and MPAG are well characterized in kidney transplantation. 8) They have also been reported in some autoimmune diseases. [9] [10] [11] [12] Renal function is well known to affect the pharmacokinetics of MPA and MPAG in kidney transplantation. [6] [7] [8] Kidney transplant recipients generally have a single kidney working sufficiently, and their glomerular filtration rate can be different from SLE patients. 9, 10) There have been a few reports on the influence of renal function on the pharmacokinetics of MPA and MPAG in autoimmune diseases. Joy et al. reported that oral clearance of MPA was predicted by creatinine clearance and the serum concentration of albumin in lupus nephritis patients. 11) In contrast to this, Neumann et al. reported that the pharmacokinetics of MPA seemed to be less affected by renal function in autoimmune diseases patients compared with kidney transplant recipients.
12) The influence of renal function on the pharmacokinetics of MPA and MPAG differs somewhat between reports.
Therapeutic drug monitoring of MPA is effective in order to avoid acute rejection and adverse drug reactions in kidney transplantation. 13, 14) The protein binding rate of MPA is 97-99% in patients with normal renal and liver function. 5) MPA is mainly bound to albumin in serum. Determination of the plasma concentration of free MPA is also recommended in kidney transplantation. 15) Free fractions of MPA and MPAG have not been reported in SLE patients in whom hypoalbuminemia often develops. Zahr et al. reported that the 12-h area concentration time curve (AUC 0-12 ) of MPA was significantly correlated with the serum concentration of albumin in SLE patients. 16) Factors affecting the free fractions of MPA and MPAG are less clear in SLE patients.
The effects of metal medication on the pharmacokinetics of MPA and MPAG in kidney transplantation [17] [18] [19] remain controversial, because co-administered cyclosporine can affect the pharmacokinetic interactions between metals and MPA or MPAG.
17) The bioavailability of MMF is decreased with iron medication in rheumatoid arthritis patients 20) and with calcium administration in healthy subjects. 21 ) Aluminum hydroxide and calcium lactate are administered for prophylaxis of glucocorticoid-induced gastritis and osteoporosis in SLE patients. Iron is needed in the treatment of iron-deficiency anemia. Magnesium oxide is administered for constipation. Although metals are often co-administered in SLE patients, the influence of metal medication on the pharmacokinetics of MPA and MPAG has not been reported in these patients. The aim of this study was to identify factors affecting the pharmacokinetics of MPA and MPAG in patients in the remission maintenance phase of SLE.
MATERIALS AND METHODS

Ethics
The study was performed in accordance with the Declaration of Helsinki and guidelines on Good Clinical Practice, and the protocol was approved by the Ethics Committee of Hamamatsu University Hospital. The patients received information about the scientific aim of the study and each patient provided written informed consent.
Patients Thirty-one SLE patients in remission maintenance phase were enrolled in the present study (Table 1) . They were all outpatients and received MMF (CellCept ® , Chugai Pharmaceutical, Tokyo, Japan) and prednisolone (Prednine ® , Shionogi & Co., Ltd., Osaka, Japan) for immunosuppression. Each patient had been receiving a fixed dosage of MMF for at least one month before enrollment without any considerable adverse reactions such as diarrhea or bone marrow toxicity. It was difficult to reduce the dose of prednisolone in these patients, and they showed little response to previous treatment with cyclophosphamide, azathioprine, or mizoribine. Not any patients received cyclosporine or tacrolimus throughout the study period. The backgrounds of the patients were obtained from their medical records.
Eight patients were receiving a metal medication (metalϩ) while 23 were not (metalϪ). Three patients with constipation were treated with magnesium oxide (330 mg, twice daily, 500 mg, thrice daily, and 500 mg, thrice daily), one with gastritis was treated with magnesium oxide (200 mg, once daily) and aluminum hydroxide (400 mg, once daily), two with constipation and osteoporosis were treated with magnesium oxide (330 mg, twice daily and 1000 mg, twice daily) and calcium lactate (1000 mg, thrice daily and 1000 mg, thrice daily), one with osteoporosis was treated with calcium lactate (1000 mg, once daily), and one with iron deficiency anemia was treated with sodium ferrous citrate (50 mg, twice daily).
Clinical laboratory values such as aspartate aminotransferase, alanine aminotransferase, serum creatinine, serum albumin, red blood cell count, white blood cell count, platelet count, hemoglobin, and C-reactive protein were obtained from routine laboratory examinations. Creatinine clearance was calculated using the Cockcroft-Gault equation [(140Ϫ age)ϫbody weight (kg)/(72ϫserum creatinine)]ϫ(0.85 for women). Serum creatinine was measured using an enzymatic method. To estimate creatinine clearance, calibrated serum creatinine values obtained with the following formula were used: serum creatinine (Yaffe method)ϭ0.2ϩserum creatinine (enzymatic method). 22) Serum albumin was measured using a bromocresol purple method. Calibration curve in human serum was linear over a concentration range of 1-70 g/l for albumin. Intra-and interassay coefficients of variation of serum albumin was Ͻ3.0%.
Determination of Plasma Concentrations of Total and Free MPA and MPAG MPA and MPAG were purchased from Sigma-Aldrich Corp. (St. Louis, MO, U.S.A.) and Analytical Services International (London, U.K.), respectively. All other chemicals were analytical grade. Postprandial blood specimens were drawn into tubes containing ethylenediaminetetraacetic acid (EDTA) before the morning dose of MMF. Predose plasma concentrations (C 0 ) of total MPA and total MPAG were simultaneously determined by ion pair HPLC as previously described.
23) The lower limits of quantification of total MPA and total MPAG were 50 ng/ml and 100 ng/ml, respectively. Intra-and interassay coefficients of variation of total MPA and total MPAG were Ͻ6.5% and Ͻ5.3%, respectively. Free MPA C 0 and free MPAG C 0 were simultaneously determined as previously described. 24) In brief, 200 ml of plasma was ultrafiltrated with Nanosep ® Centrifugal Devices 30K (Pall Corp., East Hills, NY, U.S.A.) for isolation of free MPA and MPAG. The plasma ultrafiltrate was directly injected into the analytical column. Chromatographic separation was performed on a conventional octadecyl silane column (150 mmϫ4.6 mm i.d., 5 mm particle size) with acetonitrile and 30 mM tetra-n-butylammonium bromide containing 5 mM ammonium acetate at pH 9.0 (33/67, v/v) as the mobile phase. Free MPA was detected at an excitation wavelength of 310 nm and an emission wavelength of 422 nm at 30°C. MPAG was not enough fluorescent, and the wavelength of the photodiode array UV detector for MPAG was set at 250 nm. The lower limits of quantification of free MPA and free MPAG were 1 ng/ml and 200 ng/ml, respectively. Calibration curves in ultrafiltrate of human plasma were linear over a concentration range of 1-320 ng/ml for MPA and 0.2-80 mg/ml for MPAG, respectively. Intra-and interassay coefficients of variation of free MPA and free MPAG were Ͻ3.5% and Ͻ5.5%, respectively.
Statistical Analysis All statistical analyses were performed using SPSS 15.0J (SPSS Japan Inc., Tokyo). pϽ0.05 was considered to indicate statistical significance. The C 0 of MPA and MPAG were significantly correlated with MMF dose in these SLE patients (rϭ0.65, pϽ0.01 and rϭ0.53, pϽ0.01, respectively). Thus, the MPA C 0 and MPAG C 0 were normalized for the evening MMF dose to take into account the confounding factor of the MMF dose difference. The relationships between dose-normalized MPA C 0 or MPAG C 0 and creatinine clearance were investigated using Pearson's correlation coefficient test. The relationships between free fraction of MPA or MPAG and serum albumin were also investigated using Pearson's correlation coefficient test. The ratio of MPAG C 0 to MPA C 0 (MPAG C 0 /MPA C 0 ) was calculated to evaluate the MPA glucuronidation and biliary excretion of MPAG. Differences in the dose-normalized MPA C 0 , MPAG C 0 , and MPAG C 0 /MPA C 0 between the metalϩ and metalϪ SLE patients were analyzed by the nonparametric Mann-Whitney U test.
Stepwise multiple linear regression analysis (pϽ0.05 to enter and pϾ0.10 to remove) was performed to assess the dependence between dose-normalized C 0 or free fractions of MPA or MPAG and 13 predictor values (gender (man: 0 and woman: 1), age, follow-up period, aspartate aminotransferase, alanine aminotransferase, creatinine clearance, serum albumin, red blood cell count, white blood cell count, platelet count, hemoglobin, prednisolone dose, and metal medication (metalϩ: 1 and metalϪ: 0)). Standardized partial regression coefficient (b) and variance inflation factor (VIF) were obtained. b value indicates the magnitude of each predictor value. Normally, VIF values larger than 10 suggest that multicollinearity may be causing estimation problems. 756 Vol. 34, No. 5 Figure 1 shows the correlation between creatinine clearance and dose-normalized MPA C 0 or MPAG C 0 (rϭϪ0.39, pϭ0.03 and rϭϪ0.41, pϭ0.02), respectively.
RESULTS
Dependence of MPA C 0 and MPAG C 0 on Renal Function
Dependence of Free Fractions of MPA and MPAG on Serum Albumin Both free fractions of MPA and MPAG were correlated with serum concentration of albumin (rϭ Ϫ0.84, pϽ0.01 and rϭϪ0.65, pϽ0.01) (Fig. 2) .
Effects of Metal Medication on MPA C 0 and MPAG C 0 The median values of dose-normalized MPA C 0 were 0.12 (interquartile range, 0.08-0.14) and 0.19 (interquartile range, 0.14-0.29) mg/ml per mg/kg in metalϩ and metalϪ SLE patients (pϭ0.02, Fig. 3 ), respectively. The median values of dose-normalized MPAG C 0 were 1.38 (interquartile range, 0.93-2.25) and 2.19 (interquartile range, 1.64-4.06) mg/ml per mg/kg in metalϩ and metalϪ SLE patients (pϭ0.13), respectively, and those of MPAG C 0 /MPA C 0 were 11.2 (interquartile range, 6.31-14.0) and 8.73 (interquartile range, 6.67-10.4) in metalϩ and metalϪ SLE patients (pϭ0.41), respectively.
Stepwise Multiple Regression Analysis for MPA C 0 and MPAG C 0 Creatinine clearance and metal medication were significant predictors accounting for the variability of dosenormalized MPA C 0 (pϽ0.01 and pϽ0.01) ( Table 2) . Their b values were Ϫ0.471 and Ϫ0.463, respectively. The equation acquired with multiple regression analysis accounted for 30.5% of the interindividual variability in dose-normalized MPA C 0 (pϭ0.01). Dose-normalized MPAG C 0 was significantly correlated with only creatinine clearance in multiple regression analysis (bϭϪ0.410, pϭ0.03). The acquired equation accounted for 13.5% of the interindividual variability in dose-normalized MPAG C 0 (pϭ0.03).
Stepwise Multiple Regression Analysis for Free Fractions of MPA and MPAG The medians of absolute free MPA C 0 and free MPAG C 0 were 19.8 ng/ml and 4.28 mg/ml (interquartile range, 8.6-30.6 ng/ml and 2.72-7.35 mg/ml), respectively. The free fraction of MPA was significantly correlated with only the serum concentration of albumin in multiple regression analysis (bϭϪ0.844, pϽ0.01) ( Table 2 
DISCUSSION
This study evaluated the factors affecting the pharmacokinetics of MPA and MPAG in patients in the remission maintenance phase of SLE. Higher creatinine clearance and metal medication were associated with lower MPA C 0 . Higher serum concentrations of albumin were related to lower free fractions of MPA and MPAG. Metal medication also influenced the free fraction of MPAG. To the best of our knowledge, there have not been any other studies on the influence of metal medication on the pharmacokinetics of MPA and MPAG in SLE patients.
Creatinine clearance was significantly correlated with MPA C 0 and MPAG C 0 in SLE patients (Fig. 1) . Glomerular filtration rate directly affected the renal clearance of MPA in this current study. MPA can be eliminated into urine to some extent in kidney transplant recipients. 6, 7) We have previously reported that the difference in the pharmacokinetics of MPA and MPAG between kidney transplant recipients and lupus nephritis patients may occur due to preserved renal function in lupus nephritis patients.
9) The contribution of renal clearance to total clearance of MPA is rather small in kidney transplant recipients 5) because the tubular excretion of MPA is saturated in clinical situations. 6) Renal clearance of MPA would be larger in SLE patients with both kidneys and higher creatinine clearance. In addition, renal function affected MPAG C 0 in the current study. MPAG is converted back to MPA during enterohepatic recirculation. The magnitude of enterohepatic recirculation in relation to total exposure was reported to be 40% in healthy subjects. 5) MPA AUC 0-12 was increased 38% after T-tube clamping in liver transplant recipients, because of the restoration of the enterohepatic recirculation.
25) The influence of enterohepatic recirculation of MPA may also be remarkable in SLE patients.
A significant difference in MPA C 0 but not in MPAG C 0 /MPA C 0 was observed between metalϩ and metalϪ SLE patients (Fig. 3) . The lower MPA C 0 in metalϩ SLE patients was due to the formation of a chelate complex consisting of MPA and metal cation. 21) Metal medication did not influenced on MPA glucuronidation in this study and previous study. 19) This is the first report in which a co-administered metal had an influence on the pharmacokinetics of MPA and MPAG in SLE patients, however, separate analyses in various kinds of metal will clarify what metals really decrease the plasma concentrations of MPA and MPAG. The ionic radii of metal cations are unique, and the impact of chelate complexes consisting of metal cations and MPA may be different depending on the metal. 21) However, this study indicates that some metal medications decrease free concentration of MPA.
Multiple regression analysis revealed that creatinine clearance and metal medication affected the pharmacokinetics of MPA and MPAG in the SLE patients, however, the constant acquired in multiple regression analysis implied that other factors had a greater effect than renal function and metal medication.
The free fraction of MPA was significantly correlated with the serum concentration of albumin. Atcheson et al. reported a cutoff value for serum albumin of 31 g/l, which differentiated a normal from an elevated percentage of free MPA using receiver operating characteristic curve analysis in kidney transplant recipients. 15) This inconsistency between the current study and their report on the correlation of the free fraction of MPA to the serum concentration of albumin is most likely due to the narrow range in the serum concentration of albumin in this study compared to their patients. In addition, the plasma concentration of MPAG was lower in the SLE patients owing to better renal function. The cutoff value for the serum concentration of albumin may be relatively lower in SLE patients, because the displacement of MPA from its albumin binding site by MPAG would be small.
The free fraction of MPAG was increased with metal medication in multiple regression analysis. The increase in the free fraction of MPAG was related to the increase in MPAG clearance and decrease in MPA derived from biliary-excreted MPAG. In addition to chelate complex, an increase in the free fraction of MPAG may be another possible mechanism causing the lower plasma concentrations of MPA and MPAG in patients with metal medication. This finding would seem to indicate that metals displace MPAG from its albumin binding site and increase MPAG clearance, although the interaction has not been reported in either SLE patients or kidney transplant recipients. Co-administered magnesium or aluminum is most likely only slightly absorbed. Naito et al. suggested that a pharmacokinetic interaction between metals and MPA derived from biliary-excreted MPAG probably occurred in the gastrointestinal tract. 19) Another possible reason is a confounding factor, including the influence of diseases treated with metal medication. For example, absorbance of MMF might be low in patients with constipation. However, other diseases such as osteoporosis and iron deficiency anemia seemed not associated with drug absorbance. Further study is needed to identify the reason for the increase in free MPAG with metal medication. 758 Vol. 34, No. 5 Multiple regression analysis showed that the free fraction of MPAG decreased in older patients. The free fraction of MPAG decreases in patients with a higher serum concentration of albumin, lower plasma concentration of MPAG, and the cessation of other drugs that compete with MPAG for albumin binding. Age was not positively correlated to any of the conditions described above. Joy et al. reported that the renal clearance of MPAG was negatively correlated with age in lupus nephritis patients. 11) They suggested that the increase in age was indirectly associated with the decrease in glomerular filtration rate. However, creatinine clearance was not significantly correlated with the free fraction of MPAG in the current study. Further study is needed to clarify the relationship between age and the free fraction of MPAG.
In conclusion, renal function and metal medication influenced the pharmacokinetics of MPA and MPAG in SLE patients in remission maintenance phase. In addition, the serum concentration of albumin may be useful for estimating the free concentration of MPA.
